Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBT (2020 - 2025)

Barinthus Biotherapeutics' EBT history spans 6 years, with the latest figure at -$11.2 million for Q4 2025.

  • For Q4 2025, EBT rose 45.79% year-over-year to -$11.2 million; the TTM value through Dec 2025 reached -$66.6 million, down 8.83%, while the annual FY2025 figure was -$66.6 million, 8.83% down from the prior year.
  • EBT reached -$11.2 million in Q4 2025 per BRNS's latest filing, up from -$14.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $14.8 million in Q2 2022 to a low of -$25.0 million in Q2 2023.
  • Average EBT over 5 years is -$12.6 million, with a median of -$16.1 million recorded in 2021.
  • Peak YoY movement for EBT: soared 236.33% in 2022, then tumbled 1195.21% in 2023.
  • A 5-year view of EBT shows it stood at -$16.7 million in 2021, then crashed by 38.93% to -$23.2 million in 2022, then grew by 21.88% to -$18.1 million in 2023, then dropped by 13.68% to -$20.6 million in 2024, then soared by 45.79% to -$11.2 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's EBT are -$11.2 million (Q4 2025), -$14.6 million (Q3 2025), and -$21.2 million (Q2 2025).